Skip to content
OpenCapital
Get started

Enanta Pharmaceuticals ENTA Q3 2025 Annual earnings

Reported November 17, 2025 · Before market open

Revenue$15.1MMiss by $845.6K
EPS-$0.87Beat by $0.26
Revenue estimate$16.0M
EPS estimate-$1.13

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$16.8M
EPS estimate-$0.51

Versus estimates

Revenue

Q1 2026$17.2MBeat by $131.7KQ4 2025$18.6MBeat by $2.7M
Q3 2025$15.1MMiss by $845.6K
Q2 2025$18.3MBeat by $2.3MQ1 2025$14.9MMiss by $1.0MQ4 2024$17.0MMiss by $290.3K

Diluted EPS

Q1 2026-$0.45Beat by $0.01Q4 2025-$0.42Beat by $0.12
Q3 2025-$0.87Beat by $0.26
Q2 2025-$0.85Beat by $0.40Q1 2025-$1.06Miss by $0.02Q4 2024-$1.05Beat by $0.11

Ask the moment Enanta Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Enanta Pharmaceuticals report Q3 2025 earnings?
Enanta Pharmaceuticals (ENTA) reported Q3 2025 earnings on November 17, 2025 before market open.
What were Enanta Pharmaceuticals's Q3 2025 revenue and EPS?
Enanta Pharmaceuticals reported revenue of $15.1M and eps of $-0.87 for Q3 2025.
Did Enanta Pharmaceuticals beat estimates in Q3 2025?
Revenue missed the consensus estimate of $16.0M by $845.6K. EPS beat the consensus estimate of $-1.13 by $0.26.
How did Enanta Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 77.6% from $67.6M a year earlier and eps grew 36.0% from $-1.36.
Where can I find Enanta Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-284633) and the 10-K periodic report (0001193125-25-288121) directly on SEC EDGAR. The filing index links above go to sec.gov.